HCA Healthcare Inc (HCA)

In the past six months (October 2025 - April 2026), HCA Healthcare's stock has experienced fluctuations. In October 2025, HCA Healthcare raised its yearly profit and revenue forecasts, anticipating sustained demand for medical procedures, which led to a 5% rise in premarket trading. However, the company later warned that full-year profits for 2026 were expected to be at the lower end of its guidance, partly due to the impact of Hurricanes Helene and Milton in 2024. More recently, in March 2026, HCA shares saw an increase, hitting a 4-week high of $549.87. Conversely, in April 2026, the stock decreased to $461.44, marking a 15-week low, and also experienced a 4-week low of $521.77 in March 2026. Overall, the stock's price increased by 48.72% over the last 12 months, but decreased by 7.78% in the past month as of April 11, 2026.

Demand for HCA Healthcare's products and services is not cyclical in the traditional sense, as medical needs are generally not postponed indefinitely. However, the way care is delivered is evolving, with a growing trend towards outpatient and ambulatory services, which HCA Healthcare has been actively expanding. The company has reported consistent patient acuity levels and a broad-based increase in patient volumes across various service lines, including cardiac procedures, obstetrics, and neonatal volumes. This indicates a steady and evolving demand for healthcare services, with HCA adapting its offerings to meet these shifts.

HCA Healthcare, Inc. is a global for-profit operator of healthcare facilities, headquartered in Nashville, Tennessee, and founded in 1968. The company operates within the healthcare sector, primarily in the Hospitals and Ambulatory Surgery Centers industries. HCA Healthcare's major products and services encompass a comprehensive range of medical care, including inpatient and outpatient care, emergency services, surgical services, diagnostic and imaging services, and laboratory services. They offer specialized care across numerous areas such as cardiology, oncology, orthopedics, neurology, pediatrics, and women's care. Beyond direct patient care, HCA is also a significant provider of clinical and medical education, being the largest sponsor of graduate medical education programs in the U.S. and having a majority stake in Galen College of Nursing.

HCA Healthcare has an extensive geographic footprint, operating approximately 190 hospitals and around 2,500 ambulatory sites of care across 19 U.S. states and the United Kingdom. A significant portion of its U.S. facilities are concentrated in high-growth Sunbelt markets, with the most hospitals located in Texas (73) and Florida (49). The company also maintains a strong presence in Tennessee, its founding state, with 17 hospitals.

HCA Healthcare has maintained a strong brand reputation in the past year, receiving several notable recognitions. For the 12th consecutive year, HCA Healthcare was named on Fortune's "World's Most Admired Companies" list in both 2025 and 2026, ranking first overall in its industry. In 2025, Fortune also recognized HCA Healthcare on its "America's Most Innovative Companies" list. Furthermore, HCA Healthcare was named one of the 2026 World's Most Ethical Companies by Ethisphere for the 16th time. The company's response to hurricanes Helene and Milton in 2024, deploying over 700 colleagues to disaster areas and contributing $1.5 million to relief efforts, also positively impacted its reputation.

HCA Healthcare's ownership is primarily held by institutional investors, who collectively hold about 91% of the stock. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., State Street Corp, Capital World Investors, Fmr Llc, Geode Capital Management, Llc, First Eagle Investment Management, LLC, Wellington Management Group Llp, and Norges Bank. Key individual owners include co-founder Thomas F. Frist Jr., who owns more than 20% of the company, and his sons, Thomas Frist III and William Frist, who are board members. Other significant individual shareholders include Patricia F. Elcan and Patricia C. Frist.